Hikmat A. Al-Ahmadie, MD

Associate Attending Pathologist, Memorial Hospital

Hikmat A. Al-Ahmadie, MD

Associate Attending Pathologist, Memorial Hospital
Pictured: Hikmat Al-Ahmadie

Lab Phone


My research focuses 0n identifying the molecular and genetic characterizations of subsets of urothelial carcinoma that are associated with aggressive behavior such as small-cell carcinoma and plasmacytoid/signet ring-cell carcinoma, or those that harbor specific genetic aberrations that can be subjected to targeted therapy such as FGFR3 mutations and Her2 amplification. Our findings support the presence of unique genotype-phenotype correlation in these subsets of bladder cancer, as in the case of tumors that harbor mutations in FGFR3 and CDH1.

Recognizing this correlation may help to prospectively select patients for targeted therapy. We are also trying to determine the functional and clinical relevance of these alterations on tumor biology.

In addition, I am a collaborator on a number of research projects to define the genetic landscape of bladder cancer, both with investigators at our institution and in national efforts such as The Cancer Genome Atlas.


Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.

MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.

Hikmat A. Al-Ahmadie discloses the following relationships and financial interests:

  • AstraZeneca
    Professional Services and Activities
  • Paige.AI, Inc.
    Professional Services and Activities (Uncompensated)

The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.

This page and data include information for a specific MSK annual disclosure period (January 1, 2022 through disclosure submission in spring 2023). This data reflects interests that may or may not still exist. This data is updated annually.

Learn more about MSK’s COI policies here. For questions regarding MSK’s COI-related policies and procedures, email MSK’s Compliance Office at [email protected].

View all disclosures